| The cost of treating community-acquired pneumonia MS Niederman, JS McCombs, AN Unger, A Kumar, R Popovian Clinical therapeutics 20 (4), 820-837, 1998 | 809 | 1998 |
| Awareness, knowledge, and perceptions of biosimilars among specialty physicians H Cohen, D Beydoun, D Chien, T Lessor, D McCabe, M Muenzberg, ... Advances in therapy 33, 2160-2172, 2016 | 227 | 2016 |
| Treatment cost of acute exacerbations of chronic bronchitis MS Niederman, JS McCombs, AN Unger, A Kumar, R Popovian Clinical therapeutics 21 (3), 576-591, 1999 | 208 | 1999 |
| Drug tendering: drug supply and shortage implications for the uptake of biosimilars G Dranitsaris, I Jacobs, C Kirchhoff, R Popovian, LG Shane ClinicoEconomics and Outcomes Research, 573-584, 2017 | 69 | 2017 |
| Assessing the value of biosimilars: a review of the role of budget impact analysis S Simoens, I Jacobs, R Popovian, L Isakov, LG Shane Pharmacoeconomics 35, 1047-1062, 2017 | 56 | 2017 |
| Global acceptance of biosimilars: importance of regulatory consistency, education, and trust E Cazap, I Jacobs, A McBride, R Popovian, K Sikora The oncologist 23 (10), 1188-1198, 2018 | 51 | 2018 |
| Biosimilars: practical considerations for pharmacists JG Stevenson, R Popovian, I Jacobs, S Hurst, LG Shane Annals of Pharmacotherapy 51 (7), 590-602, 2017 | 39 | 2017 |
| Can biosimilars help achieve the goals of US health care reform? R Boccia, I Jacobs, R Popovian, G de Lima Lopes Jr Cancer management and research, 197-205, 2017 | 22 | 2017 |
| Sowing confusion in the field: the interchangeable use of biosimilar terminology L McKinley, JM Kelton, R Popovian Current medical research and opinion 35 (4), 619-621, 2019 | 14 | 2019 |
| Pharmaceutical Care Environment on the Health Care Expenditures of Medicare HMO Enrollees R Popovian Journal of Managed Care Pharmacy 5 (5), 414-419, 1999 | 13 | 1999 |
| Accessibility of adult immunizations in pharmacies compared to physician offices in low-income communities R Popovian, W Winegarden, E Rivera, K Gavigan Journal of the American Pharmacists Association 62 (5), 1644-1647, 2022 | 9 | 2022 |
| US consumers overpay for generic drugs E Trish, K Van Nuys, R Popovian Schaeffer Center White Paper Series 10, m589-2268, 2022 | 7 | 2022 |
| Nonsteroidal anti-inflammatory drugs: The need for assessment and education SM Setter, C Corbett, BJ Gates, C Terriff, CA Johns, DA Sclar, R Popovian Home care provider 6 (3), 100-105, 2001 | 6 | 2001 |
| Waiving COVID-19 vaccine patents: a bad idea and a dangerous precedent PJ Pitts, R Popovian, W Weingarden Journal of Commercial Biotechnology 26 (2), 2021 | 5 | 2021 |
| Analysis of Drug Formulary Exclusions from the Patient’s Perspective: 2023 Update S Chea, AM Sydor, R Popovian medRxiv, 2023.11. 01.23297921, 2023 | 3 | 2023 |
| Analysis of drug formulary exclusions from the patient's perspective R Popovian, AM Sydor, P Pitts Health Science Journal 16 (3), 1-4, 2022 | 3 | 2022 |
| An estimate of the net benefits from prior authorization policies in the US R Popovian, W Winegarden Health Science Journal 15 (4), 1-4, 2021 | 3 | 2021 |
| Modeling the Effects of Formulary Exclusions: How Many Patients Could Be Affected by a Specific Exclusion? AM Sydor, E Bergin, J Kay, E Stone, R Popovian Journal of Health Economics and Outcomes Research 11 (1), 86, 2024 | 1 | 2024 |
| Most physicians unable to estimate patients’ out-of-pocket costs: How pharmacists can help S Collins Pharmacy Today 28 (3), 38, 2022 | 1 | 2022 |
| Cash-based pharmacies deliver transparency, savings S Collins Pharmacy Today 27 (5), 32, 2021 | 1 | 2021 |
